Safety and Efficacy Study to Treat Bacterial Vaginosis

August 20, 2013 updated by: Medicis Global Service Corporation

A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis

The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

651

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States
    • Arizona
      • Phoenix, Arizona, United States
    • California
      • La Mesa, California, United States
      • Los Angeles, California, United States
      • San Diego, California, United States
      • Torrance, California, United States
    • Colorado
      • Denver, Colorado, United States
    • Connecticut
      • Groton, Connecticut, United States
    • Florida
      • Boyton Beach, Florida, United States
      • Clearwater, Florida, United States
      • Miami, Florida, United States
      • North Miami, Florida, United States
      • Sunrise, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
      • Augusta, Georgia, United States
      • Roswell, Georgia, United States
    • Illinois
      • Chicago, Illinois, United States
    • Louisiana
      • Marrero, Louisiana, United States
    • Massachusetts
      • Falls River, Massachusetts, United States
    • Michigan
      • Detroit, Michigan, United States
      • Saginaw, Michigan, United States
    • Nebraska
      • Lincoln, Nebraska, United States
    • New Jersey
      • Lawrenceville, New Jersey, United States
      • Neptune, New Jersey, United States
      • Plainsboro, New Jersey, United States
    • Ohio
      • Columbus, Ohio, United States
    • Pennsylvania
      • Jenkintown, Pennsylvania, United States
      • Philadelphia, Pennsylvania, United States
    • South Carolina
      • Columbia, South Carolina, United States
    • Tennessee
      • Jackson, Tennessee, United States
    • Texas
      • Corpus Christi, Texas, United States
      • Houston, Texas, United States
      • Schertz, Texas, United States
    • Vermont
      • Williston, Vermont, United States
    • Virginia
      • Virginia Beach, Virginia, United States
    • Washington
      • Seattle, Washington, United States
      • Tacoma, Washington, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Have a clinical diagnosis of bacterial vaginosis as determined by the investigator.
  • Other items as identified in the protocol.

Exclusion Criteria:

  • Have a known or suspected other infectious cause of vulvovaginitis.
  • Other items as identified in the protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Vehicle
Treatment with the vehicle (placebo)
The vehicle vaginal gel in an applicator (placebo).
Experimental: Product 55394
Treatment with product 55394
Product 55394 vaginal gel in a prefilled applicator.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Cure
Time Frame: Day 21
The proportion of subjects with a clinical cure at the Day 21 visit, as assessed by the investigator.
Day 21

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Therapeutic Cure
Time Frame: Day 21
The proportion of subjects with a therapeutic cure at the Day 21 visit. Therapeutic cure is defined as both a clinical cure and bacteriological cure as assessed by the investigator and the central laboratory, respectively.
Day 21

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ron Staugaard, Medicis Pharmaceutical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

October 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

June 14, 2012

First Submitted That Met QC Criteria

June 15, 2012

First Posted (Estimate)

June 18, 2012

Study Record Updates

Last Update Posted (Estimate)

August 21, 2013

Last Update Submitted That Met QC Criteria

August 20, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • MP-1601-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe